The earnings call revealed strong revenue growth and customer satisfaction but was overshadowed by the revision of revenue guidance due to macroeconomic challenges and market competition. While European regulatory approval presents a long-term opportunity, short-term challenges persist, affecting performance and outlook.

Company Guidance -

Q2 2025

During the recent RxSight conference call, the company provided revised guidance for fiscal year 2025, reflecting anticipated revenue in the range of $160 million to $175 million, down from the previous estimate of $185 million to $197 million. This adjustment reflects an implied revenue growth of 14% to 25% compared to 2024, a reduction from the initial 32% to 41% growth projection. The company anticipates selling more Light Delivery Devices (LDDs) in 2025 than in 2024, despite potential economic headwinds affecting Light Adjustable Lens (LAL) procedures. First-quarter 2025 revenue was reported at $37.9 million, marking a 28% increase from the same period in the previous year but a 6% sequential decline from the fourth quarter of 2024. The gross margin guidance remains unchanged at 71% to 73%, while operating expenses are adjusted to $150 million to $160 million, down from the prior forecast of $165 million to $170 million, reflecting a focus on aligning expenses with revenue growth.

Revenue Growth

Preliminary first quarter 2025 revenue was $37.9 million, up 28% compared to the year-ago quarter.

European Regulatory Approval

RxSight reported European regulatory approval for their LDD and LAL, marking a significant step towards expanding into the EU market.

Customer Satisfaction

Customer satisfaction reached an all-time high of 97%, indicating strong approval of RxSight's products and services.

LDD Installed Base Growth

The LDD installed base grew to 1,044 units, up 43% compared to the end of the first quarter of 2024.

RxSight (RXST) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

RXST Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	-0.24 / -	-0.16	―	―	―
May 07, 2025	2025 (Q1)	-0.22 / -0.20	-0.25	20.00% (+0.05)	―
Feb 25, 2025	2024 (Q4)	-0.17 / -0.15	-0.26	42.31% (+0.11)	―
Nov 07, 2024	2024 (Q3)	-0.25 / -0.16	-0.35	54.29% (+0.19)	―
Aug 05, 2024	2024 (Q2)	-0.22 / -0.16	-0.4	60.00% (+0.24)	―
May 06, 2024	2024 (Q1)	-0.29 / -0.25	-0.42	40.48% (+0.17)	―
Feb 28, 2024	2023 (Q4)	-0.37 / -0.26	-0.56	53.57% (+0.30)	―
Nov 09, 2023	2023 (Q3)	-0.43 / -0.35	-0.61	42.62% (+0.26)	―
Aug 07, 2023	2023 (Q2)	-0.47 / -0.40	-0.61	34.43% (+0.21)	―
May 09, 2023	2023 (Q1)	-0.53 / -0.42	-0.64	34.38% (+0.22)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

RXST Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 07, 2025	$14.90	$13.23	-11.21%
Feb 25, 2025	$29.21	$28.97	-0.82%
Nov 07, 2024	$50.85	$48.01	-5.59%
Aug 05, 2024	$40.78	$47.85	+17.34%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does RxSight (RXST) report earnings?

RxSight (RXST) is schdueled to report earning on Aug 07, 2025, After Close (Confirmed).

What is RxSight (RXST) earnings time?

RxSight (RXST) earnings time is at Aug 07, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is RXST EPS forecast?

RXST EPS forecast for the fiscal quarter 2025 (Q2) is -0.24.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing